Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
The new generation conjugate trastuzumab deruxtecan (Т-DXd) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer (BC) who have previously received a drug regimen containing anti-HER2 targeted agents, as well as for the treatment of adult patien...
Saved in:
Main Authors: | R. A. Murashko, S. V. Sharov, E. P. Chashnikova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2025-03-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/1322 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01) -
Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023-10-01) -
Modeling the impact of using trastuzumab deruxtecan in patients with breast cancer on reducing cancer mortality in Russia
by: N. A. Avxentyev, et al.
Published: (2024-07-01) -
Target therapy in treatment of HER2-positive breast cancer
by: A. S. Belokhvostova, et al.
Published: (2016-02-01) -
Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)